Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Dermatol Ther
; 33(1): e13190, 2020 01.
Article
en En
| MEDLINE
| ID: mdl-31863534
ABSTRACT
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type-2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type-2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has the potential to inhibit both IL-4 and IL-13. We propose IL-4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Penfigoide Benigno de la Membrana Mucosa
/
Penfigoide Ampolloso
/
Pénfigo
/
Anticuerpos Monoclonales Humanizados
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article